Northwest Biotherapeutics develops personalized cancer vaccines using a patient's own immune cells, targeting brain tumors and solid tumors.
The company has no revenue, with net losses of $0.06B in 2025 and $0.08B in 2024, relying on funding to sustain operations.
Its DCVax platform is proprietary, but clinical and regulatory hurdles are high; competitors like Bristol Myers and Merck dominate immuno-oncology, making the moat weak.
Key events, in time order
None yet
None yet
The narrative centers on DCVax, a glioblastoma vaccine, with a patient's letter to UK officials highlighting its use. The discussion focuses on patient access and treatment.
Main discussion
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
